Risks of lithium toxicity in patients taking ACEi or ARB medications no greater than those taking beta blockers: Cohort study

Lithium remains the gold standard for treating and preventing manic episodes in bipolar disorder, but it has a narrow safety window. Studies have been conflicting on whether initiating an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARB) in patients taking lithium can result in lithium toxicity. Researchers examined this issue in a population-based cohort study in Ontario, Canada of adults 50 years and older who were co-prescribed an oral ACEi or ARB (n = 2,267) or a beta blocker (n = 2,110) while taking lithium. Beta-blockers were used as a comparator because they are prescribed for similar indications as ACEis and ARBs, but do not increase the risk of lithium toxicity. The researchers found no increase in 90-day risk of hospital admission with lithium toxicity during co-prescription of an ACEi or ARB with lithium compared with co-prescription of a beta-blocker. “These results support the continued use of ACE inhibitors or ARBs in lithium users when indicated; however, due to study limitations, we cannot draw firm conclusions,” the researchers wrote. “These findings should not be interpreted as evidence that ACE inhibitors or ARBs are universally safe with lithium, but rather that concomitant use may be feasible in selected patients when appropriate clinical caution and monitoring are undertaken.” Ahmadi, F., Muanda, F. T., McArthur, E., et al. (2026, Aug 5). Lithium toxicity from angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker co-prescription: A population-based cohort study. J Psychopharmacol, 2698811261473401. https://doi.org/10.1177/02698811261473401 Online ahead of print.

Publication Details

Journal
The Brown University Psychopharmacology Update
Published
2026-11-14
DOI
https://doi.org/10.1002/pu.31524
Primary Topic
Bipolar Disorder and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Risks of lithium toxicity in patients taking ACEi or ARB medications no greater than those taking beta blockers: Cohort study

The Brown University Psychopharmacology Update
Bipolar Disorder and Treatment
article

Risks of lithium toxicity in patients taking ACEi or ARB medications no greater than those taking beta blockers: Cohort study

article en

Abstract

Lithium remains the gold standard for treating and preventing manic episodes in bipolar disorder, but it has a narrow safety window. Studies have been conflicting on whether initiating an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARB) in patients taking lithium can result in lithium toxicity. Researchers examined this issue in a population-based cohort study in Ontario, Canada of adults 50 years and older who were co-prescribed an oral ACEi or ARB (n = 2,267) or a beta blocker (n = 2,110) while taking lithium. Beta-blockers were used as a comparator because they are prescribed for similar indications as ACEis and ARBs, but do not increase the risk of lithium toxicity. The researchers found no increase in 90-day risk of hospital admission with lithium toxicity during co-prescription of an ACEi or ARB with lithium compared with co-prescription of a beta-blocker. “These results support the continued use of ACE inhibitors or ARBs in lithium users when indicated; however, due to study limitations, we cannot draw firm conclusions,” the researchers wrote. “These findings should not be interpreted as evidence that ACE inhibitors or ARBs are universally safe with lithium, but rather that concomitant use may be feasible in selected patients when appropriate clinical caution and monitoring are undertaken.” Ahmadi, F., Muanda, F. T., McArthur, E., et al. (2026, Aug 5). Lithium toxicity from angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker co-prescription: A population-based cohort study. J Psychopharmacol, 2698811261473401. https://doi.org/10.1177/02698811261473401 Online ahead of print.

The Brown University Psychopharmacology UpdateVol. 37(12)
Bipolar Disorder and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon